Translational Research

The Laboratory of Translational Research, led by Dr. Joel Moss, focuses on clinical and translational areas of investigation.

On This Page
Joel Moss

Clinical Trials and Studies

Estudio del proceso de la enfermedad en la linfangioleiomiomatosis

RECLUTAMIENTO
Todas las edades
All
No Se Aceptan Voluntaries Saludables
Este estudio intenta comprender los genes y las proteínas que son responsables de provocar daño pulmonar en los pacientes con LAM. Para participar en este estudio, debe tener entre 16 y 99 años y se le debe haber diagnosticado LAM. Este estudio se lleva a cabo en Bethesda (Maryland).

Albuterol nebulizado o inhalado para la linfangioleiomiomatosis

RECLUTAMIENTO
Adultos, Ancianos
Femenino
No Se Aceptan Voluntaries Saludables
Este estudio examina qué método de administración del albuterol (inhalado o nebulizado) es mejor para mejorar la función pulmonar en mujeres adultas con LAM. Para participar en este estudio, debe ser mujer, tener entre 18 y 80 años y se le debe haber diagnosticado LAM. Este estudio se lleva a cabo en Bethesda (Maryland).

Role of Genetic Factors in the Development of Lung Disease

Recruiting
All Ages
All Genders
Accepting Healthy Volunteers
Do you or your child have a lung disease? This study will investigate the genes involved in the breathing process and in the development of lung diseases such as asthma or sarcoidosis to improve understanding of the role they play. To participate in this study, you or your child must be between 2 and 90 years old. This study is located in Bethesda, Maryland, at the NIH Clinical Center.

Cutaneous Tumorigenesis in Patients with Tuberous Sclerosis

Recruiting
Adult, Older Adult
All Genders
Not Accepting Healthy Volunteers
Do you have tuberous sclerosis and want to help researchers better understand the disease? This study is investigating what causes multiple skin tumors to develop in people with tuberous sclerosis. To participate in the study, you must be at least 18 years old. This study is located at the NIH Clinical Center in Bethesda, Maryland.

Descubrimiento de biomarcadores sensibles al sirolimus en la sangre

RECLUTAMIENTO
Adultos, Ancianos
Femenino
No Se Aceptan Voluntaries Saludables
El objetivo de este estudio es identificar la dosis correcta de sirolimus para tratar personas que tienen LAM. Para participar en este estudio, debe ser mujer, tener entre 18 y 90 años y se le debe haber diagnosticado LAM. Este estudio se lleva a cabo en Bethesda (Maryland).

Featured Publications

Effect of beta-agonists on LAM progression and treatment.

Authors: Le K, Steagall WK, Stylianou M, Pacheco-Rodriguez G, Darling TN, Vaughan M, Moss J.
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E944-E953
Read Publication

Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis.

Authors: Gopalakrishnan V, Yao J, Steagall WK, Avila NA, Taveira-DaSilva AM, Stylianou M, Chen MY, Moss J.
Chest. 2019 May 01;155(5):962-971
Read Publication

Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients.

Authors: Taveira-DaSilva AM, Julien-Williams P, Jones AM, Stylianou M, Moss J.
Eur Respir J. 2018 Apr 19;51(4):1702258
Read Publication

PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.

Authors: Mashimo M, Bu X, Aoyama K, Kato J, Ishiwata-Endo H, Stevens LA, Kasamatsu A, Wolfe LA, Toro C, Adams D, Markello T, Gahl WA, Moss J.
JCI Insight. 2019 Feb 21;4(4):e124519
Read Publication

Role of a TRIM72 ADP-ribosylation cycle in myocardial injury and membrane repair.

Authors: Ishiwata-Endo H, Kato J, Tonouchi A, Chung YW, Sun J, Stevens LA, Zhu J, Aponte AM, Springer DA, San H, Takeda K, Yu ZX, Hoffmann V, Murphy E, Moss J
JCI Insight 2018 Nov 15;3(22):
Read Publication
View More Publications

Meet the Team

Joel Moss

Joel Moss, M.D., Ph.D.

Senior Investigator

Joel Moss graduated summa cum laude from Brandeis University in 1966 with a B.A. in chemistry and earned his M.D. and Ph.D. degrees from New York University School of Medicine in 1972. Following internship and residency at Johns Hopkins Hospital, Dr. Moss joined the NHLBI in 1974 as a research associate and pulmonary fellow. Since 2007, he has been head of the Translational Research Section and of the Lymphangioleiomyomatosis (LAM) Research Program. Dr. Moss has received multiple awards, including LAM Foundation Award (1999 and 2010), and the New York University Alumni Achievement Award in Basic Science in 2009. Dr. Moss is an honorary member of the Peruvian Thoracic Society and received the Chiba (Japan) Medical Society Award. He is also a member of American Society for Clinical Investigation for which he was a Councillor and Vice-President. In 2009, Dr. Moss was elected to the Johns Hopkins University Society of Scholars. He is a Fellow of the American College of Chest Physicians. Dr. Moss has authored or coauthored more than 630 papers, edited and co-authored several books and is a co-inventor of several patents. Dr. Moss has been an editor of the Journal of Biological Chemistry and the Journal of Clinical Investigation. He is currently an Editor of the American Journal of Respiratory Cell and Molecular Biology and is a designated Associate Editor of CHEST through 2015.

Load more members